South Korea's Samsung Bioepis has submitted a marketing authorization application to the European Medicines Agency (EMA) for SB2, a biosimilar of autoimmune drug Remicade (infliximab) for moderate to severe rheumatoid arthritis.
Samsung Bioepis, a joint venture with Biogen Idec ($BIIB), has completed head-to-head studies on the original from Merck & Co. ($MRK) and Johnson & Johnson ($JNJ).
Earlier this year, South Korea's Celltrion launched its Remicade biosimilar, dubbed Remsima, in Europe.
Celltrion's co-exclusive partner, Hospira ($HSP), markets the biosimilar independently as Inflectra in Europe.
SB4, a Samsung Bioepis biosimilar of autoimmune drug Enbrel (etanercept) from Amgen ($AMGN) and Pfizer ($PFE), is also under EMA marketing authorization review.
- get more from Samsung Bioepis